Viscofan World You are in: The Viscofan Group EN | ES
Global

The Viscofan Group

EN | ES
Europe

Belgium

EN

Czech Republic

CS | EN

Germany

DE

Serbia

EN | SR

Spain

ES
Americas

Brazil

PT

Canada

EN | FR

Mexico

ES

United States

EN

Uruguay

ES
Asia & Oceania
Viscofan BioEngineering
Viscofan releases its 2023FY results
29/February/2024

Main highlights of the January-December 2023 results:

• Net turnover is €1,225.8 million, 2.1% higher than the previous year and 4.2% in like-for-like terms.

• EBITDA of €268.4 million, a growth of 0.5% compared to the previous year and 7.9% in like-for-like terms.

• €141.0 million in Net Profit, 1.1% up on the previous year.

• €138.0 million net bank debt at year-end 2023, higher than the €101.3 million at the end of the previous year after payment of the interim dividend of €1.40 per share in December 2023.

• €3.00 per share of total shareholder remuneration proposed in the 2023 profit distribution, €2.00 per share in ordinary terms, and an extraordinary remuneration of €1.00 per share.

• José Domingo de Ampuero y Osma, Chairman of the Viscofan Group:

"The 2023 financial year was marked by the first decline in the casings market in the last twenty-four years. An exceptional situation that has coexisted with an environment of high costs in our production inputs.

In a more adverse context than expected, the strength of our business model and our ability to adapt have enabled us to reach new all-time highs with year-on-year growth in terms of revenues, EBITDA and net income. However, the main financial figures are below the targets foreseen for 2023.

Having implemented the major organic transformation projects envisaged in the Beyond25 plan, some of which are delivering operational results in line with or above initial estimates, we are well positioned to grow significantly in revenue, EBITDA and net profit in 2024, while we expect the market to return to historical growth rates.

In view of the prospect of higher operating cash flows than foreseen in the Beyond25 strategic plan, the Board of Directors has resolved to submit to the General Shareholders' Meeting the approval of extraordinary shareholder remuneration. Thus, the total remuneration per share expected for the 2023 financial year is €3.0, of which €2.0 is ordinary and €1.0 is extraordinary.”

Please, find all results information on the Investor Relations site LINK



® Viscofan Group